Printed From BioPortfolio.com
PARP inhibitor can be new treatment option for patients with metastatic breast cancer, BRCA mutations
16:45 EST 8 Dec 2017 | News-Medical.net
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Original Article: PARP inhibitor can be new treatment option for patients with metastatic breast cancer, BRCA mutations
